Acorda Therapeutics, Inc. (NASDAQ:ACOR) has a beta value of 1.45 and has seen 1,632,088 shares traded in the last trading session. The company, currently valued at $24.45 Million, closed the last trade at $0.51 per share which meant it gained $0.06 on the day or 12.54% during that session. The ACOR stock price is -635.29% off its 52-week high price of $3.75 and 17.65% above the 52-week low of $0.42. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.37 Million shares traded. The 3-month trading volume is 2.08 Million shares.
The consensus among analysts is that Acorda Therapeutics, Inc. (ACOR) is a Hold stock at the moment, with a recommendation rating of 3. 1 analysts rate the stock as a Sell, while none rate it as Overweight. 3 out of 5 have rated it as a Hold, with 1 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.31.
Acorda Therapeutics, Inc. (NASDAQ:ACOR) trade information
Sporting 12.54% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Sep 15 when the ACOR stock price touched $0.55 or saw a rise of 7.27%. Year-to-date, Acorda Therapeutics, Inc. shares have moved -75%, while the 5-day performance has seen it change 7.05%. Over the past 30 days, the shares of Acorda Therapeutics, Inc. (NASDAQ:ACOR) have changed -23.42%. Short interest in the company has seen 11Million shares shorted with days to cover at 5.29.
Wall Street analysts have a consensus price target for the stock at $3, which means that the shares’ value could jump 488.24% from current levels. The projected low price target is $1 while the price target rests at a high of $5. In that case, then, we find that the current price level is +880.39% off the targeted high while a plunge would see the stock lose 96.08% from current levels.
Acorda Therapeutics, Inc. (ACOR) estimates and forecasts
Figures show that Acorda Therapeutics, Inc. shares have underperformed across the wider relevant industry. The company’s shares have lost -35.89% over the past 6 months, with this year growth rate of -4.65%, compared to 13.7% for the industry. Other than that, the company has, however, increased its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are 32.6% and -193.3% for the next quarter. Revenue growth from the last financial year stood is estimated to be -38%.
5 analysts offering their estimates for the company have set an average revenue estimate of $29.29 Million for the current quarter. 5 have an estimated revenue figure of $28.31 Million for the next quarter concluding in December 01, 2020. Year-ago sales stood $44.72 Million and $50.5 Million respectively for this quarter and the next, and analysts expect sales will grow by -34.5% for the current quarter and -43.9% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +16.45% over the past 5 years. Earnings growth for 2020 is a modest +4.7% while over the next 5 years, the company’s earnings are expected to increase by 29%.
Acorda Therapeutics, Inc. (NASDAQ:ACOR)’s Major holders
Insiders own 1.49% of the company shares, while shares held by institutions stand at 116.94% with a share float percentage of 118.71%. Investors are also buoyed by the number of investors in a company, with Acorda Therapeutics, Inc. having a total of 162 institutions that hold shares in the company. The top two institutional holders are Vanguard Group, Inc. (The) with over 4.01 Million shares worth more than $2.94 Million. As of June 29, 2020, Vanguard Group, Inc. (The) held 8.35% of shares outstanding.
The other major institutional holder is Renaissance Technologies, LLC, with the holding of over 3.85 Million shares as of June 29, 2020. The firm’s total holdings are worth over $2.83 Million and represent 8.03% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Explorer Fund, Inc. As of June 29, 2020, the former fund manager holds about 2.85% shares in the company for having 1366942 shares of worth $1Million while later fund manager owns 775.33 Thousand shares of worth $746.26 Thousand as of April 29, 2020, which makes it owner of about 1.62% of company’s outstanding stock.